化疗联合或不联合EGFR-TKI治疗EGFR-TKI获得性耐药晚期肺腺癌患者的临床观察  

Clinical observation of chemotherapy combined with or without EGFR-TKI in the treatment of advanced acquired EGFR-TKI resistant lung adenocarcinoma

作　　者：缪亚军[1] 张亮[1] 杨莉[1] 

机构地区：[1]南通市第一人民医院肿瘤科,江苏南通226000

出　　处：《现代肿瘤医学》2018年第8期1216-1219,共4页Journal of Modern Oncology

摘　　要：目的:观察化疗联合或不联合表皮生长因子受体-络氨酸激酶抑制剂(EGFR-TKI)治疗晚期获得性EGFR-TKI耐药肺腺癌患者的临床疗效及不良反应。方法:收集2011年1月至2015年12月南通市第一人民医院治疗晚期获得性EGFR-TKI耐药肺腺癌患者60例,采用随机数字表法分为研究组(化疗联合EGFR-TKI)30例和对照组(单纯化疗)30例,对比两组近期疗效、血清肿瘤标志物指标及不良反应发生情况。结果:研究组的近期疗效缓解率(20.0%)高于对照组(16.6%),但差异无统计学意义(P>0.05);两组皮疹、恶心、呕吐及肝功能损害发生率差异有统计学意义(P<0.05);治疗后研究组的血清癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角质蛋白19(CK19)片段(CYFRA 21-1)水平与对照组相似,差异无统计学意义(P>0.05)。结论:对于EGFR-TKI耐药的晚期肺腺癌患者,单纯化疗方案更有优势。Objective：To observe the clinical efficacy and side effects of chemotherapy combined with or without EGFR - TKI in the treatment of advanced acquired EGFR - TKI resistant lung adenocarcinoma. Methods： Sixty patients with EGFR -TKI drug -resistant lung adenocarcinoma from January 2011 to December 2015 in Nantong First People＇s Hospital were collected, and they were randomly divided into research group （chemotherapy combined with EGFR -TKI） with 30 cases and control group（ chemotherapy alone） with 30 cases. The two groups of short -term efficacy, tumor markers and adverse reactions were compared. Results：Short - term efficacy （20.0%） in research group was higher than that of the control group （ 16.6 % ） , but the difference was not statistically significant （ P 〉 0.05 ）. The incidence of rash, nausea, vomiting and liver damage in the two groups was significantly different （ P 〈 0.05 ）. After treatment, serum earcinoembryonic antigen（CEA） , neuron specific enolase （ NSE ） and cytokeratin 19 （ CYFRA 21 - 1 ） in the research group were similar to those in the control group, there was no significant difference （ P 〉 0.05 ）. Conclusion：For EGFR -TKI -resistant advanced lung adenocarcinoma patients, chemotherapy alone has advantage.

关 键 词：非小细胞肺癌 表皮生长因子受体-酪氨酸激酶抑制剂 获得性耐药 

分 类 号：R734.2[医药卫生—肿瘤]